Repetto Horatio A
Service of Pediatrics, Hospital Nacional Prof. Dr. Alejandro Posadas, Cervino 3900, 3p. Buenos Aires 1425, Argentina.
Kidney Int Suppl. 2005 Aug(97):S102-6. doi: 10.1111/j.1523-1755.2005.09717.x.
In the classic form of hemolytic uremic syndrome associated with toxins of gram-negative enterobacteria, mortality in the acute stage has been lower than 5% since 1978 (data from the Nephrology Committee, Argentine Society of Pediatrics). Children usually die because of severe involvement of the central nervous system, intestine, or myocardium and its complications, or because of intercurrent infection. Treatment in this phase is supportive, and efforts should be put into prevention of infection by Shiga-like toxin-producing enterohemorrhagic Escherichia coli. Of the 95% who survive, approximately one third is at risk for having chronic sequelae. Motor, sensory, or intellectual deficits, intestinal strictures, myocardial infarctions, or diabetes are infrequent. The more-frequent chronic renal lesion is characterized by the hyperfunction of nephrons remaining after the acute necrotizing lesion, which leads to progressive scarring, and not by persistence or recurrence of the microangiopathic process. Three courses of progression to end-stage renal failure have been described. Children with most severe forms do not recover from acute renal failure and enter directly into a dialysis and transplantation program. A second group recovers renal function partially, with persistent proteinuria and frequently hypertension; progression to end-stage renal failure occurs in 2 to 5 years. The third group may recover normal serum creatinine and creatinine clearance, with persistent proteinuria. They are at risk of progressing to chronic renal failure and end-stage renal disease after more than 5 years, and sometimes as late as 20 years, after the acute disease. Treatment should aim at preventing the mechanisms associated with progressive renal scarring. Transplantation is indicated in this form of hemolytic uremic syndrome, because there is little, if any, risk of recurrence, and the prognosis is similar to that of transplantation for other diseases.
在与革兰氏阴性肠道杆菌毒素相关的典型溶血尿毒综合征中,自1978年以来急性期死亡率低于5%(数据来自阿根廷儿科学会肾脏病委员会)。儿童通常死于中枢神经系统、肠道或心肌的严重受累及其并发症,或死于并发感染。此阶段的治疗是支持性的,应努力预防产志贺样毒素的肠出血性大肠杆菌感染。在存活的95%患者中,约三分之一有发生慢性后遗症的风险。运动、感觉或智力缺陷、肠道狭窄、心肌梗死或糖尿病并不常见。较常见的慢性肾脏病变的特征是急性坏死性病变后残留肾单位的功能亢进,这会导致进行性瘢痕形成,而非微血管病变过程的持续或复发。已描述了三种进展至终末期肾衰竭的病程。最严重形式的儿童无法从急性肾衰竭中恢复,直接进入透析和移植程序。第二组部分恢复肾功能,伴有持续性蛋白尿且常伴有高血压;在2至5年内进展至终末期肾衰竭。第三组血清肌酐和肌酐清除率可能恢复正常,但有持续性蛋白尿。他们在急性疾病后5年以上,有时甚至在20年后,有进展为慢性肾衰竭和终末期肾病的风险。治疗应旨在预防与进行性肾瘢痕形成相关的机制。在这种形式的溶血尿毒综合征中,建议进行移植,因为复发风险很小(如果有风险的话),且预后与其他疾病移植的预后相似。